When did Bioblast Pharma's stock split?

Bioblast Pharma's stock reverse split on the morning of Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Bioblast Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO) , Synergy Pharmaceuticals (SGYP) , Immunomedics (IMMU) , Verastem (VSTM) , Voyager Therapeutics (VYGR) , Athersys (ATHX) , ContraFect (CFRX) , CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO) .

NASDAQ:ORPN

Bioblast Pharma (ORPN) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ORPN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.39
▼
$1.52
50-Day Range: $11.50
▼
$28.49
52-Week Range: $6.16
▼
$30.00

Volume: 92,329 shs
Average Volume: N/A
Market Capitalization: $588,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Bioblast Pharma alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Bioblast Pharma Stock (NASDAQ:ORPN)

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

ORPN Stock News Headlines

April 10, 2024 | markets.businessinsider.com

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

March 14, 2024 | barrons.com

AnaptysBio Inc.

April 19, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

February 23, 2024 | msn.com

What's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?

February 23, 2024 | morningstar.com

Lantern Pharma Inc Ordinary Shares LTRN

February 18, 2024 | msn.com

QBiotics wins FDA orphan status for rainforest-derived cancer drug

February 18, 2024 | seekingalpha.com

PBSV Pharma-Bio Serv, Inc.

February 5, 2024 | markets.businessinsider.com

AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis

April 19, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

January 4, 2024 | markets.businessinsider.com

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

November 3, 2023 | marketwatch.com

Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation

March 31, 2023 | wsj.com

Changzhou Qianhong Bio-Pharma Co. Ltd. A

March 1, 2023 | marketwatch.com

2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for Development

February 18, 2023 | marketwatch.com

Spinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028

February 15, 2023 | marketwatch.com

Spinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028

February 13, 2023 | thestreet.com

BioBlast Scant Data Links Drug to Improved Swallowing in Patients

January 30, 2023 | seekingalpha.com

BioMarin: Opportunity To Score Home Run With Latest Regulatory Advancements

January 18, 2023 | marketwatch.com

Spinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028

October 16, 2022 | finance.yahoo.com

Orphan Drugs Market Size to Hit USD 340.84 Billion by 2027

September 21, 2022 | seekingalpha.com

ENLV Enlivex Therapeutics Ltd.

August 31, 2022 | marketwatch.com

BioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans Progressiva

August 31, 2022 | msn.com

BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate

August 12, 2022 | finance.yahoo.com

Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease

August 11, 2022 | seekingalpha.com

BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript

August 1, 2022 | finance.yahoo.com

Biosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromes

July 12, 2022 | markets.businessinsider.com

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma

July 8, 2022 | apnews.com

Global Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.com

See More Headlines

Receive ORPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ORPN
CUSIP: N/A
CIK: 1596812
Web: bioblastpharma.com
Phone: (722) 670-8072
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.56 per share
Price / Book: 0.19

Miscellaneous

Outstanding Shares: 420,000
Free Float: N/A
Market Cap: $588,000.00
Optionable: Not Optionable
Beta: 1.41

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Oren Hershkovitz
Chief Executive Officer
Shachar Shlosberger
Chief Financial Officer
Dror Mevorach
Chief Scientific & Medical Officer
Odelia Ben-Shitrit
Head-Clinical Operations

Key Competitors

View All Competitors

ORPN Stock Analysis - Frequently Asked Questions

When did Bioblast Pharma's stock split?: Bioblast Pharma's stock reverse split on the morning of Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What other stocks do shareholders of Bioblast Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO).

This page (NASDAQ:ORPN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bioblast Pharma (ORPN) Stock Price, News & Analysis

About Bioblast Pharma Stock (NASDAQ:ORPN)

ORPN Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ORPN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info